Phathom Pharmaceuticals Competitors

Atea Pharmaceuticals (NASDAQ:AVIR) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Profitability

This table compares Atea Pharmaceuticals and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Atea Pharmaceuticals and Phathom Pharmaceuticals, as provided by MarketBeat.com.

Atea Pharmaceuticals presently has a consensus target price of $69.3333, indicating a potential upside of 25.35%. Phathom Pharmaceuticals has a consensus target price of $53.00, indicating a potential upside of 39.47%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Earnings & Valuation

This table compares Atea Pharmaceuticals and Phathom Pharmaceuticals' gross revenue, earnings per share and valuation.

Institutional & Insider Ownership

73.8% of Phathom Pharmaceuticals shares are held by institutional investors. 39.8% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biohaven Pharmaceutical (NYSE:BHVN) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Profitability

This table compares Biohaven Pharmaceutical and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

Biohaven Pharmaceutical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Biohaven Pharmaceutical and Phathom Pharmaceuticals, as reported by MarketBeat.

Biohaven Pharmaceutical currently has a consensus price target of $96.4545, indicating a potential upside of 36.29%. Phathom Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 39.47%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Biohaven Pharmaceutical.

Valuation & Earnings

This table compares Biohaven Pharmaceutical and Phathom Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats Biohaven Pharmaceutical on 7 of the 11 factors compared between the two stocks.

Sage Therapeutics (NASDAQ:SAGE) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Institutional & Insider Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 4.8% of Sage Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Sage Therapeutics and Phathom Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Phathom Pharmaceuticals has lower revenue, but higher earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Sage Therapeutics and Phathom Pharmaceuticals, as reported by MarketBeat.

Sage Therapeutics currently has a consensus price target of $87.0625, indicating a potential upside of 16.58%. Phathom Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 39.47%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Sage Therapeutics.

Volatility & Risk

Sage Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Profitability

This table compares Sage Therapeutics and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Phathom Pharmaceuticals beats Sage Therapeutics on 7 of the 13 factors compared between the two stocks.

Phathom Pharmaceuticals (NASDAQ:PHAT) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Phathom Pharmaceuticals and Hutchison China MediTech's top-line revenue, earnings per share and valuation.

Hutchison China MediTech has higher revenue and earnings than Phathom Pharmaceuticals. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Phathom Pharmaceuticals and Hutchison China MediTech, as provided by MarketBeat.com.

Phathom Pharmaceuticals presently has a consensus target price of $53.00, indicating a potential upside of 39.47%. Hutchison China MediTech has a consensus target price of $40.00, indicating a potential upside of 36.52%. Given Phathom Pharmaceuticals' higher possible upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Hutchison China MediTech.

Volatility and Risk

Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Hutchison China MediTech has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Phathom Pharmaceuticals and Hutchison China MediTech's net margins, return on equity and return on assets.

Phathom Pharmaceuticals (NASDAQ:PHAT) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Phathom Pharmaceuticals and Emergent BioSolutions' top-line revenue, earnings per share and valuation.

Emergent BioSolutions has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Phathom Pharmaceuticals and Emergent BioSolutions, as provided by MarketBeat.com.

Phathom Pharmaceuticals presently has a consensus target price of $53.00, indicating a potential upside of 39.47%. Emergent BioSolutions has a consensus target price of $109.8333, indicating a potential upside of 44.78%. Given Emergent BioSolutions' stronger consensus rating and higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Phathom Pharmaceuticals.

Volatility and Risk

Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Profitability

This table compares Phathom Pharmaceuticals and Emergent BioSolutions' net margins, return on equity and return on assets.

Summary

Emergent BioSolutions beats Phathom Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

Phathom Pharmaceuticals (NASDAQ:PHAT) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Phathom Pharmaceuticals and Arena Pharmaceuticals' top-line revenue, earnings per share and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Phathom Pharmaceuticals and Arena Pharmaceuticals, as provided by MarketBeat.com.

Phathom Pharmaceuticals presently has a consensus target price of $53.00, indicating a potential upside of 39.47%. Arena Pharmaceuticals has a consensus target price of $91.80, indicating a potential upside of 41.75%. Given Arena Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Phathom Pharmaceuticals.

Volatility and Risk

Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Phathom Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Arena Pharmaceuticals beats Phathom Pharmaceuticals on 9 of the 12 factors compared between the two stocks.